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Abstract
Introduction: Studies suggest that the HIV-1 epidemic in the Netherlands may have become more virulent, leading to faster
disease progression if untreated. Analysis of CD4 cell count decline before antiretroviral therapy (ART) initiation, a surrogate
marker for disease progression, may be hampered by informative censoring as ART initiation is more likely with a steeper
CD4 cell count decline.
Methods: Development of CD4 cell count from 9 to 48 months after seroconversion was analyzed using a mixed-effects
model and 2 models that jointly modeled CD4 cell counts and time to censoring event (start ART, ,100 CD4 cells/mm3, or
AIDS) among therapy-naı¨ve MSM HIV-1 seroconverters in the Netherlands. These models make different assumptions about
the censoring process.
Results: All 3 models estimated lower median CD4 cell counts 9 months after seroconversion in later calendar years (623,
582, and 541 cells/mm3 for 1984–1995 [n = 111], 1996–2002 [n = 139], and 2003–2007 seroconverters [n = 356], respectively,
shared-parameter model). Only the 2 joint-models found a trend for a steeper decline of CD4 cell counts with
seroconversion in later calendar years (overall p-values 0.002 and 0.06 for the pattern-mixture and the shared-parameter
model, respectively). In the shared-parameter model the median decline from 9 to 48 months was 276 cellsmm3 for 1984–
1995 seroconverters and 308 cells/mm3 for 2003–2007 seroconverters (difference in slope, p = 0.045).
Conclusion: Mixed-effects models underestimate the CD4 cell decline prior to starting ART. Joint-models suggest that CD4
cell count declines more rapidly in patients infected between 2003 and 2007 compared to patients infected before 1996.
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Introduction
The higher the HIV-1 plasma level, the more likely progression
to AIDS is [1] and the higher the chance of HIV-1 transmission
[2]. Previously, we found an increasing trend over time in plasma
HIV-1 RNA concentration at set-point, i.e., 9 to 27 months after
HIV-1 seroconversion and an accompanying decreasing trend of
CD4 cell count measured at viral set-point [3]. In the Amsterdam
Cohort Studies (ACS), a higher replicative fitness of HIV-1 isolates
obtained from participants with seroconversion in more recent
years was found [4]. Some cohorts have reported a similar increase
in HIV-1 RNA concentration and decrease in CD4 cell count at
viral set-point over time [5–7], whereas others found no evidence
for such changes [8,9]. The effect of higher viral load and lower
CD4 T-cell count at set-point on progression to AIDS or death is
difficult to study in the combination antiretroviral therapy (cART)
era as these endpoints are hardly observed in effectively treated
patients. A surrogate marker of disease progression is the rate of
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CD4 cell decline in patients not on therapy. Since individuals with
low CD4 cell counts are more likely to start antiretroviral therapy
(ART), the presence of informative censoring needs to be
considered. Mixed-effects models, the standard method of analysis
of longitudinal data, can give biased estimates when censoring
(here: the start of ART) is not at random and depends on
unobserved CD4 cell counts [10]. Joint-modeling of longitudinal
CD4 cell counts together with the censoring process can give
unbiased estimates, under certain assumptions. Therefore, we
investigated trends in CD4 cell count decline between 9 months
and 4 years after HIV seroconversion, using regression models that
make different assumptions about the censoring pattern.
Methods
Patient Selection
Data were obtained from men having sex with men (MSM)
participating in the ACS or the AIDS therapy evaluation in the
Netherlands (ATHENA) cohort. ACS recruitment started in 1984,
mainly among MSM living in or around Amsterdam. Inclusion
criteria varied over time [11]. The ATHENA cohort has been
described elsewhere [12] and includes anonymized data obtained
from treated and untreated HIV-infected patients, who have been
followed in or after 1996 in any of the 25 HIV treatment centers
and also includes ACS participants in care in or after 1996.
From both cohorts, MSM from Western-Europe and North-
America were selected with a maximum interval between the last
negative and first positive HIV-1 antibody test of 1 year. The day
of seroconversion was estimated as midpoint between both tests.
Also included were MSM with serological evidence of acute
infection in which case the day of seroconversion was set 1 month
prior to the date of the first positive test. All MSM with
seroconversion before 1996 were from the ACS. At seroconver-
sion, all patients were 16 years or older. Patients had at least one
CD4 cell count between 9 and 27 months after seroconversion
while being ART-naı¨ve. Subtype infections other than subtype B
were excluded. MSM without subtype determination were
included, since in our cohort the prevalence of subtype B infection
among MSM from Western-Europe or North-America is 95% and
therefore highly likely [12].
Ethics Statement
Informed written consent is obtained from all ACS participants,
and the study has been approved by the Medical Ethical
Committee of the Academic Medical Centre. Ethical approval
in the ATHENA cohort is not obtained as data are collected from
patients as part of HIV care. Patients can opt-out after being
informed by their treating physician of the purpose of collection of
clinical data.
Outcome
CD4 cell counts in peripheral blood measured between 9
months and 4 years after seroconversion were used to model CD4
cell count decline. The 4-year threshold ensured a similar follow-
up period for subjects seroconverting in early and in later years.
Only CD4 cell counts obtained from samples taken prior to any of
the following 3 dates were included for analysis: date of first
starting ART, first date CD4 cell count had dropped below 100
cells/mm3 (other studies [5,8] have censored CD4 cell counts after
this date because of the possibility of an accelerated decline), and
the date 1 year prior to AIDS diagnosis (CD4 cell count decline
may accelerate around this date [13,14]).
Statistical Analysis
Trends in CD4 cell decline over time were analyzed using 3
models with different underlying assumptions. All models assumed
a linear decline and included a random slope and intercept for
each patient. Age at seroconversion (linearly modeled and
centered at 35 years of age) and timing of seroconversion (either
in 3 categories 1984–1995, 1996–2002, 2003–2007, or as a
continuous variable using natural splines with knots at January
1993, 2000 and 2005) were included as fixed covariates. cART
was introduced in the Netherlands as standard of care in 1996 and
this motivated our first group 1984–1995 (pre-cART era). The
second cut-off was chosen a-priori so that each time period was
sufficiently wide and included a sufficient number of patients. We
used 3 different statistical models: 1) Mixed-effects models. These
models can provide unbiased estimates if censoring only depends
on the observed CD4 cell counts, given covariates included in the
model (the censoring process is missing at random (MAR)). If
instead censoring depends on unobserved CD4 counts, such as the
underlying subject-specific CD4 cell count trajectories, estimates
will be biased. Joint-modeling of longitudinal CD4 cell counts and
the censoring process can give unbiased estimates under certain
assumptions [15]. We used two joint-modeling approaches: 2)
pattern-mixture models; and 3) shared-parameter models [16].
Pattern mixture model. Pattern-mixture models quantify
the longitudinal outcome conditionally on the timing of the
censoring event. The censoring event was either ART initiation,
CD4 cell count dropping below 100 cells/mm3 or an AIDS
diagnosis (in which case CD4 cell counts were censored from the
date 1 year before the AIDS diagnosis). We used seven distinct
patterns: censoring between 9–21, 21–27, 27–33, 33–39, 39–48
months, lost to follow-up (including suicide). A seventh pattern was
no censoring event within 48 months. The basic probability
structure of the model is:
p CD4i,cens patterni Dhð Þ
~p CD4i Dcens patterni,hð Þp cens patternið Þ
ð1Þ
With i an arbitrary individual and h a categorical variable
representing the 3 seroconversion periods 1984–1995, 1996–2002
and 2003–2007. The joint distribution in (1) is obtained by
multiplying pattern-specific probabilities of CD4 trajectories
p CD4i Dcens patterni,hð Þ, modelled via a random effects model,
by weights according to the probability distribution,
p cens patternið Þ. The parameter estimates of the CD4 trajectories,
and their dependence on h, are obtained via likelihood maximisa-
tion. The weights from the second term. are obtained by dividing
the number of patients in each pattern and in each period by the
total number of patients in each period [17].
Shared parameter model. The basic probability structure
of the model is:
p CD4i,Ti Dhð Þ~p CD4i Dhð Þp Ti DCD4ið Þ ð2Þ
with i and h as above and Ti the time to the censoring
event.p CD4i Dhð Þ in (2) represents a longitudinal random effects
model for the longitudinal CD4 cell counts and p Ti DCD4ið Þ a
survival model for the time to censoring due to ART initiation,
CD4 cell count dropping below 100 cells/mm3 or an AIDS
diagnosis. Individuals that had complete follow-up were treated as
censored cases. The survival model was regressed on the
underlying CD4 cell count and age. We used a Weibull
accelerated failure time model, but a Cox proportional hazards
model gave similar results. In the shared-parameter model, the
CD4 Cell Count Decline Trends after HIV Infection
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association between the censoring times and CD4 cell counts is
modeled via a set of random effects. Conditional on the random
effects, the longitudinal CD4 cell counts are independent of the
censoring time, CD4 cell counts were cube root transformed to
comply with normality assumptions. Both terms contribute to the
likelihood, hence a joint likelihood was maximized.
Averaged mean estimates from the pattern-mixture model were
estimated using PROC MIXED in SAS 9.2 (SAS Institute, Cary,
NC). The obtained standard errors are slightly underestimated
because the size of the patterns are assumed fixed. To correct for
the uncertainty of pattern sizes, corrected standard errors can be
obtained using the delta method [17,18]. Shared-parameter
modeling was done using the R (R Development Core Team
2010) package JM [19]. SAS and R syntax is given in Supporting
Information S1.
Results
In total, 606 patients were included in the study: 111 with
seroconversion between 1984 and 1995, 139 between 1996 and
2002, and 356 between 2003 and 2007. Of all MSM, 9 (8%) out of
120 with seroconversion between 1984 and 1995, 122 (47%) out of
261 with seroconversion between 1996 and 2002, and 165 (32%)
out of 521 with seroconversion between 2003 and 2007, were
excluded because either the date of ART initiation, the date CD4
cell count had dropped below 100 cells/mm3, or the date 1 year
prior to diagnosis of AIDS was before 9 months after seroconver-
sion. A last negative HIV test within 1 year of the first positive test
was available for 524 patients. The remaining 82 patients had
serological evidence of acute infection (3 seroconverters between
1984 and 1995, 15 between 1996 and 2002, and 64 between 2003
and 2007).
Baseline characteristics are shown in Table 1. Subtype was not
determined in 330 patients (54%). The percentage of samples
measured using a single-platform method gradually increased from
0% prior to 1997 to 94% in 2010. Timing of the first sample taken
after 9 months after seroconversion was similar between the 3
seroconversion periods. Overall, the median first CD4 cell count at
9 months was 540 cells/mm3 but it decreased with later periods of
seroconversion. The proportion of patients with a censoring event
increased over time. ART was started in 295 patients, in 30
patients AIDS was diagnosed, and in 14 patients CD4 cell count
declined to below 100 cells/mm3.
Intercepts (estimated CD4 cell count at 9 months after
seroconversion) were similar between the 3 models (see Table 2).
All models showed a significant association of a lower CD4 cell
count at 9 months with seroconversion in later calendar years.
Estimates of the decline in CD4 cell count obtained with the
mixed-effects model did not differ significantly between periods of
seroconversion (overall p-value = 0.56). However, in the pattern-
mixture model there was a significant association of an increasing
CD4 cell count decline with seroconversion in later years
(p = 0.002) whilst in the shared parameter model there was a
borderline trend (p = 0.06). In both joint-models, the decline for
2003–2007 seroconverters was significantly higher than for 1984–
1995 seroconverters. In the shared-parameter model, the differ-
ence was 0.12
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/year (95% CI 0.00, 0.24). Estimates
obtained with the pattern-mixture model showed a similar trend,
although the rate of decline was steeper across all seroconversion
periods compared to the shared-parameter model. In both joint
models the decline did not differ significantly between serocon-
version periods 1996–2002 and 2003–2007. Figure 1a–c shows the
estimated decline in CD4 cell count graphically, on the original
scale. When modeled using splines (Figure 2), the association
between year of seroconversion and slope was borderline
significant in the shared-parameter model (p = 0.06) but not in
the mixed-effects model (p = 0.32). As expected, the estimates from
the mixed-effects and the shared-parameter model differed least
during the period when ART was not available. Shared-parameter
model estimates suggest that the CD4 decline became smaller over
time before 1993 and became larger thereafter. However, 95%
confidence intervals were wide.
There was no significant association between age and the mean
CD4 cell count 9 months after seroconversion in any of the 3
models. Nor did the mixed-effects and pattern-mixture models
find an association between age and the slope of decline in CD4
cell count after 9 months (20.03
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/year, 95% CI
20.08, 0.02 and, 0.01
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/year, 95% CI 20.03, 0.05
per 10-year increase in age, respectively). The shared-parameter
model estimated a stronger association between decline in CD4
cell count and older age; 20.06
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/year per 10-year
increase in age, 95% CI 20.12, 20.01.
For a typical seroconverter, i.e., an individual 36 years of age at
seroconversion, with a median CD4 cell count at 9 months, the
median decline between 9 and 48 months (see Table 3) in the
pattern-mixture model changed from 286 CD4 cells/mm3 for
1984–1995 seroconverters (on average 88 cells/mm3/year) to 363
cells/mm3 for 2003–2007 seroconverters (112 cells/mm3/year). In
the shared-parameter model the estimated median decline was
smaller (83 cells/mm3/year for 1984–1995, and 90 cells/mm3/
year for 2003–2007 seroconverters) whereas the mixed-effects
model decline estimates were substantially smaller (between 75
and 77 cells/mm3/year across the 3 periods) compared to the
pattern-mixture model estimates. Table 3 also shows that the
pattern-mixture model estimated the median time from serocon-
version to the 350 CD4 cells/mm3 threshold was 2.2 years for
2003–2007 seroconverters compared to 3.8 years for 1984–1995
seroconverters. This compares to 2.7 years and more than 4.0
years for the shared-parameter model.
Discussion
Using joint-models, we found a trend of a steeper CD4 cell
count decline before the initiation of antiretroviral therapy in HIV
infected MSM since the early nineties. This suggests, together with
the earlier reported higher viral fitness and the plasma viral load
and lower CD4 cell count at viral set-point, an increasing trend in
HIV virulence in MSM followed in HIV treatment centers in the
Netherlands over time [3,4]. Likewise, a recent meta-analysis
concluded that virulence may have increased over the course of
the HIV-1 pandemic [20]. The trend of a steeper CD4 cell count
decline over time was only apparent when timing of censoring
(because of ART initiation or disease progression) was jointly
modeled with longitudinal CD4 cell counts and not when mixed-
effects models were used. Mixed-effects models can provide
unbiased estimates when the probability of the censoring event
only depends on the observed CD4 cell counts (the MAR
assumption), given covariates included in the model. Provided
that the model for the censoring event is correctly specified, joint-
models can provide unbiased estimates both when data are MAR,
and when censoring is informative (when censoring depends on
aspects of CD4 cell count that are not observed). The different
results obtained from mixed-effects models and joint-models in this
study, indicates that censoring CD4 cell counts due to ART
initiation or disease progression is informative and estimates from
standard mixed-effects models are probably incorrect. Estimation
of parameters in joint models, compared to mixed-effect models, is
more complex and joint models are currently not routinely used.
CD4 Cell Count Decline Trends after HIV Infection
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Using the shared-parameter model, we estimated an annual
CD4 cell count decline of around 90 cells/mm3/year for 2003–
2007 seroconverters. The pattern-mixture model estimated a
steeper decline. The reported decrease among Italian patients
included in the MASTER cohort [5] was less steep compared to
our findings (approximately 55 cells/mm3/year with a trend
towards steeper decline in more recent years for MSM). The Swiss
HIV Cohort Study (SHCS), using the same methodology as the
MASTER cohort, found no significant evidence for a changing
rate of decline between 1986 and 2002 [8]. Analyses in both these
studies were restricted to patients for whom at least 5 CD4 cell
counts were available at least 200 days after the date of confirmed
HIV infection. Furthermore, analyses were not restricted to
patients for whom the date of seroconversion could reliably be
estimated. Finally, estimates from the SHCS and MASTER
cohort were obtained using mixed-effects models, without
correction for informative dropout. The CASCADE collaboration
[21] estimated the median time between seroconversion and
Table 1. Characteristics of 606 included MSM living in the Netherlands with seroconversion between 1984 and 2007.
Year of seroconversion
1984–1995 1996–2002 2003–2007 Total
N=111 N=139 N=356 N=606
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age at seroconversion (years) 35.2 (29.7–42.1) 34.6 (30.2–41.1) 37.9 (31.6–43.8) 36.6 (30.6–43.1)
First CD4 cell count 9–27 months after seroconversion
(cells/mm3)
580 (450–850) 550 (450–720) 510 (390–660) 540 (410–710)
Months between seroconversion and first CD4 cell count 10.3 (9.9–10.7) 10.7 (9.7–12.3) 10.5 (9.6–11.9) 10.4 (9.7–11.7)
Number of included CD4 cell count measurements 13 (10–14) 6 (4–8) 7 (4–9) 7 (4–10)
Number of included CD4 cell count measurements 13 (10–14) 6 (4–8) 7 (4–9) 7 (4–10)
N (%) N (%) N (%) N (%)
Timing of censoring
9–21 months 6 (5%) 34 (24%) 76 (21%) 116 (19%)
21–27 months 4 (4%) 14 (10%) 44 (12%) 62 (10%)
27–33 months 12 (11%) 5 (4%) 29 (8%) 46 (8%)
33–39 months 4 (4%) 10 (7%) 33 (9%) 47 (8%)
39–48 months 10 (9%) 12 (9%) 46 (13%) 68 (11%)
No censoring within 48 months 67 (60%) 58 (42%) 116 (33%) 241 (40%)
Lost to follow-up 9–48 months 8 (7%) 6 (4%) 12 (3%) 26 (4%)
Reason of censoring within 48 months
Start ART 14 (39%) 68 (91%) 213 (93%) 295 (49%)
AIDS diagnosis 15 (42%) 5 (7%) 10 (4%) 30 (5%)
,100 CD4 cells/mm3 7 (19%) 2 (2%) 5 (2%) 14 (2%)
IQR: Interquartile range, MSM: men who have sex with men.
doi:10.1371/journal.pone.0064437.t001
Figure 1. CD4 cell count for a typical patient (36 years of age), backtransformed to original scale by method of estimation. Dashed
lines and shaded regions are 95% confidence intervals.
doi:10.1371/journal.pone.0064437.g001
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reaching 350 CD4 cells/mm3 in 30–35-year old MSM with
seroconversion after 1996 to be 3.94 years, similar to our mixed-
effect estimate of 3.8 years for 1996–2002 seroconverters. Our
joint-model estimates of 3.1 and 3.0 years were substantially lower
indicating the MAR assumption may not hold. The CASCADE
collaboration did not find evidence for an increased rate of CD4
cell count decline in more recent calendar years. CD4 cell count
decline was jointly modeled with survival time. However, no
correction for informative censoring due to ART initiation was
made.
Figure 2. Mean slope (fat line) of CD4 cell count and 95% CI (dashed thin lines) in
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/year according to calendar year of
seroconversion estimated using a mixed-effects model and shared-parameter model.
doi:10.1371/journal.pone.0064437.g002
Table 2. Estimates of mean CD4 cell count at 9 months after seroconversion and rate of decline in CD4 cell count between 9 and
48 months using 3 methods.
Mean CD4 cell count
at 9 months
after seroconversion,
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3
(95% CI)
Difference with
2003–2007 (95% CI)
p-value
(overall)
Mean slope,
ffiffiffiffiffiffiffiffiffi
cells3
p
/mm3/yr
(95% CI)
Difference in slope
with 2003–2007
(95% CI)
p-value
(overall)
Mixed-effects
Model
(0.0005) (0.56)
1984–1995 8.52 (8.32, 8.72) 0.43 (0.20, 0.66) 0.0002 20.42 (20.50, 20.33) 0.05 (20.05, 0.16) 0.33
1996–2002 8.35 (8.16, 8.53) 0.25 (0.04, 0.47) 0.02 20.43 (20.52, 20.33) 0.04 (20.07, 0.15) 0.47
2003–2007 8.09 (7.97, 8.21) 0.00 20.47 (20.53, 20.41) 0.00
Pattern-mixture
model
(0.002) (0.002)
1984–1995 8.55 (8.36, 8.73) 0.37 (0.19, 0.55) 0.0008 20.49 (20.60, 20.37) 0.28 (0.17, 0.40) 0.0004
1996–2002 8.42 (8.23, 8.61) 0.24 (0.05, 0.43) 0.03 20.65 (20.85, 20.45) 0.12 (20.08, 0.32) 0.30
2003–2007 8.17 (8.06, 8.29) 0.00 20.77 (20.87, 20.67) 0.00
Shared-parameter
model
(0.002) (0.06)
1984–1995 8.54 (8.34, 8.73) 0.39 (0.16, 0.62) 0.0008 20.45 (20.55, 20.35) 0.12 (0.00, 0.24) 0.045
1996–2002 8.35 (8.17, 8.53) 0.20 (20.01, 0.42) 0.06 20.49 (20.60, 20.38) 0.08 (20.04, 0.20) 0.19
2003–2007 8.15 (8.03, 8.26) 0.00 20.57 (20.64, 20.50) 0.00
In all models age at seroconversion (as a continuous variable, centered at 36 years of age) was included as an interaction term both with the CD4 cell count at 9 months
and the slope.
CI: confidence interval.
doi:10.1371/journal.pone.0064437.t002
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The reason for the less steep CD4 slope estimates and stronger
effect of older age with CD4 cell count decline in the shared-
parameter model compared to the pattern-mixture model is
unclear, but an effect of age on either CD4 cell counts at 9 months
on the slope, or both is to be expected, as shown by others [21,22].
Estimates obtained using shared-parameter models allowing the
estimated underlying CD4 cell count to have a different
association with censoring due to the start of ART and censoring
due to disease progression (censoring because of ,100 CD4 cells/
mm3, or 1 year prior to AIDS) were similar to those presented
(results not shown). Furthermore, estimates from models censoring
only CD4 cell counts because of ART initiation were also similar
to our main results (results not shown).
Combined together, the ACS and ATHENA cohorts span
almost the entire period of the Dutch HIV epidemic. A potential
weakness is that ACS participants (all 1984–1995 seroconverters
were ACS participants) might have different socioeconomic status,
race, overall health status, or might otherwise be different to
ATHENA participants. We attempted to minimize bias because of
population changes by restricting inclusion to a very homogeneous
population: MSM from Western-Europe or North-America and
likely to be infected with subtype B. Most patients from both
cohorts were seroconverters, and thus, had been tested for HIV
before, suggesting a similar health seeking behaviour. Still, the
possibility that our findings are the result of changes in patient
characteristics over time cannot be excluded. The proportion of
patients in our study identified through serological evidence of
recent HIV-1 seroconversion increased from 3% between 1984
and 1995 to 18% between 2003 and 2007. This could have biased
our results if patients went to seek medical care because of severe
acute seroconversion illness and would otherwise not have been
diagnosed. The number of symptoms during primary infection is
associated with viral load set-point [23] and some specific signs
with faster disease progression [24]. However, when these patients
were excluded, similar results were obtained (results not shown).
Single-platform techniques to determine CD4 cell counts,
gradually introduced in the late nineties, reportedly measure
lower CD4 cell counts than dual-platform techniques [25]. We did
not find a significant association between the standard CD4 cell
count measurement technology at the time of the CD4 cell count
measurement and the level of CD4 cell counts, and estimates in all
3 types of models remained similar (results not shown). However,
this adjustment may have been incomplete as CD4 cell counts may
have been measured with other techniques than the standard
method. Factors influencing the number of measured CD4 cells
which we could not control for include gating strategy, tobacco use
and the time of day that the sample was taken [25–27].
Our study did not include patients who had started ART, or
had a CD4 cell count below 100 cells/mm3 within 9 months or
AIDS within 21 months after seroconversion. As we had to
exclude a high proportion of seroconverters in the cART era for
this reason, this may have biased estimates for the 1996–2002 and
2003–2007 periods. Patients starting therapy soon after infection,
outside the setting of a randomized clinical trial, are more likely to
have low CD4 cell counts and/or a more pronounced decline.
Hence our estimates of the slope in 1996–2002 and 2003–2007
may have been upwardly biased. However, one could also argue
that 1996–2002 and 2003–2007 estimates may be downwardly
biased because patients with an early rapid CD4 cell count decline
and starting ART before 9 months may have had a slower decline
thereafter (because of regression to the mean effects) which is now
not observed because of the early start of ART. Regression to the
mean effects may have a dampening effect on bias resulting from
exclusion of patients starting early treatment.
The probability of transmission of HIV is higher when the viral
load is higher [28]. The duration of asymptomatic HIV infection
increases with lower set-point viral load [14]. Together these
factors determine the expected number of new infections an
infected person will cause during the course of infection [29].
Evidence suggests that the level of set-point viral load may be
largely determined by virus genotype [30] and that viral load
between transmitter and recipient is correlated [31–35]. This may
result in a selection of viral strains with higher set-point viral load
because the infectious period is shortened in the cART era
(transmission during successful ART is absent or near zero [36]).
The proportion of transmitters with high set-point viral load
among those transmitting HIV will increase and may lead, if viral
load between transmitter and recipient is indeed correlated, to the
observed increase in viral load and lower CD4 cell count at viral
set-point [3] and a steeper decline in CD4 cell count.
Another explanation of our finding may be changes in host
genetic factors or adaption of HIV-1 to host genetic factors [37]
[38] or a rise in superinfection incidence, associated with a higher
fitness [39]. Although dual infections can easily be missed, the
incidence of 0% between 1984 and 1997 [40] and 1 to 1.5%
between 1996 and 2007 in Amsterdam patients [41,42] suggests
that an increase over the years, caused by an increase in risk
behavior [43], is unlikely to completely explain our findings.
In summary, to minimize bias it is important to jointly model
timing of censoring because of ART initiation and/or disease
progression in the analysis of longitudinal CD4 cell count trends.
Table 3. Estimated CD4 cell count decline (cells/mm3) between 9 and 48 months and time between seroconversion and decline to
350 CD4 cells/mm3 for a typical patient (aged 36 years) according to method of estimation and period of seroconversion.
Method of estimation
Seroconversion
period
Mixed-
effects
Pattern-
mixture
Shared-
parameter
CD4 cell count decline between 9 and 48 months (cells/mm3) 1984–1995 2249 2286 2269
1996–2002 2244 2346 2274
2003–2007 2246 2363 2293
Years between seroconversion and 350 CD4 cells/mm3 1984–1995 $4.0 3.8 $4.0
1996–2002 3.8 2.8 3.4
2003–2007 3.0 2.2 2.7
doi:10.1371/journal.pone.0064437.t003
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By doing so, we found a trend for a faster CD4 cell count decline
in MSM with newly acquired HIV-1 infection between 2003 and
2007 compared to the pre-cART era. This could indicate an
increase in HIV virulence over time. The higher rate of CD4 cell
count decline, together with a lower CD4 cell count 9 months after
seroconversion, results in a shorter time period between HIV
infection and reaching the threshold of 350 CD4 cells/mm3.
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